Viscosupplementation Market By Product (Single injection, Three injection, Five injection), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025Report

Viscosupplementation Market By Product (Single injection, Three injection, Five injection), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

Published: August 2017  |  87 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-982-1

Industry Insights

The global viscosupplementation market size was valued at USD 3.01 billion in 2016 and is projected to grow with CAGR of 9.04% over the forecast period. Increasing geriatric population, rising prevalence & incidence of osteoarthritis, and growing lifestyle-induced disorders, such as obesity, are some factors expected to drive the growth of viscosupplements market during the forecast period. According to the Caspian Journal of Internal Medicine, around 13% of women and 10% of men suffer from osteoarthritis. In 2000, the American Rheumatism Association (ACR) recognized hyaluronic acid injections i.e. viscosupplementations as the first-line treatment for osteoarthritis. 

The reimbursement scenario is likely to become favorable globally making treatment for osteoarthritis affordable. Medicare reimburses 80% of the patient allowable cost and the remaining 20% depends on patients’ secondary insurer. France has a well-defined reimbursement policy thus responsible for its high share in Europe. There are 13 viscosupplementations available in the country out of which 12 are reimbursed up to 65% by Social Security, for the treatment of knee osteoarthritis. According to the International Society of Arthroscopy, Knee Surgery, and Orthopedic Sports Medicine (ISAKOS) in France, the products are reimbursed 50% of their price, which was approved once in 2001.

U.S. viscosupplementation market by product, 2014 - 2025 (USD Million)

U.S. viscosupplementation market

Presence of a strong product pipeline portfolio provides an opportunity for market expansion over the forecast period. Carbylan initiated second Phase 3 in 2016 focused on osteoarthritis treatment with and without Hydros-TA. Phase 2 provided positive results thus boosting Phase 3 trials.

As per the Osteoarthritis Research Society International (OARSI) U.S., both corticosteroids and hyaluronic acid injections can be used for the treatment of osteoarthritis, but the effect of viscosupplementations is slightly higher than that of corticosteroids.

The regulatory barriers are relatively low in countries such as South Korea, which makes it an attractive opportunity for industry players to set their footprint in these markets. Viscosupplementations are classified as specialized medication in South Korea.

Product Insights

Based on the product, the market is segmented into single injection, three injection, and five injection. Due to growing demand for shorter regimen, single-injection cycles are expected to grow at the highest CAGR over the forecast period. 

MONOVISC from Anika Therapeutics is a single-injection hyaluronic acid that received FDA approval in early 2014. Another single-injection product “CINGAL” from the same company is in the pipeline. Gel-One (Zimmer Holdings) and Synvisc-One (Sanofi) are other convenient single injections available in the market.

Regional Insights

The improvement of healthcare facilities due to economic development witnessed in the emerging countries, such as China, Japan, South Korea and India, has projected the Asia Pacific region as the potentially lucrative market. Japan was the largest Asia Pacific market in 2016. High awareness levels about single-injection treatment and greater preference for minimally invasive management of osteoarthritis is expected to drive regional market growth. 

Latin America is anticipated to observe the fastest growth over the coming years. While efficacy and safety are rated in other parts of the world, Latin Americans view reimbursement and pricing as the decisive factors while choosing hyaluronic acid treatment. The overall trend prevailing amongst doctors is to avoid knee replacement surgeries as far as possible, which has boosted demand for pain management through viscosupplementations.

Viscosupplementation Market Share, By Geography, 2016 (%)

viscosupplementation market

Competitive Insights

There is a steady growth in the industry as new players are entering the market. There are various manufacturers operating in the market who are in the process of introducing new products. HAppyCross, HAppyVisc, and HAppyMini are few products of Labrha, a France-based company. Moreover, HAppySoft (generic product) and HAppyOne (single intra-articular injection) are in the pipeline. 

While there are new entrants, the existing players are strengthening their foothold in the industry by introducing new and better products. In June 2016, Anika Therapeutics, Inc. launched CINGAL in Europe. The company intended to make the product available in Germany, Poland, Italy, Czech Republic, and Hungary. The product received CE mark in March 2016. It marks an important initiative in the company’s global expansion. In May 2017, the company presented efficacy data for CINGAL in the 2017 European Federation of National Associations of Orthopaedics and Traumatology Annual Congress. The company is undertaking various efforts to gain FDA approval in order to launch their product in the U.S

Some key industry contributors are Sanofi, Anika Therapeutics, Inc., Seikagaku Corporation, Zimmer Holdings Inc, Bioventus, Ferring B.V., Lifecore Biomedical, LLC, and LG Life Sciences Ltd

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America,& MEA

Country scope

U.S., Canada, UK, France, Japan, China, Brazil, Mexico, & South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments covered in the report

This report forecasts revenue growth and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the viscosupplements market on the basis of product and region:

  • Product Outlook (Revenue, USD Million; 2014 - 2025)

    • Single injection

    • Three injection

    • Five injection

  • Regional Outlook (Revenue, USD Million; 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • France

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA